Selank

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed by the Institute of Molecular Genetics (IMGB) of the Russian Academy of Sciences in Moscow as a pharmacologically optimised analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg). Tuftsin is a naturally occurring fragment of the heavy chain of immunoglobulin G, produced through proteolytic cleavage in the spleen and monocytes. It was originally characterised as a phagocyte-activating peptide — a signal that upregulates macrophage and neutrophil activity and has anxiolytic and mood-modifying properties in rodent models. Selank extends the tuftsin sequence at its C-terminus with Pro-Gly-Pro, a modification that dramatically improves the peptide's resistance to enzymatic degradation (particularly by prolyl endopeptidase and other peptidases that would rapidly cleave tuftsin itself) and enhances its central nervous system bioavailability and duration of action without meaningfully altering its receptor profile.

Selank has been approved as a registered prescription drug in Russia — specifically as a nasal spray formulation, brand name Selank — for the treatment of generalised anxiety disorder and asthenic conditions (states of persistent mental and physical exhaustion with cognitive dysfunction). This registration followed over two decades of preclinical and clinical research conducted primarily at Russian institutions, making Selank one of the better-characterised peptide nootropics in the clinical literature, even if that literature is predominantly in Russian-language journals and not always accessible to Western researchers. The combination of regulatory approval, a long clinical history, and an established safety record in a patient population distinguishes Selank from the majority of research peptides that lack any human clinical data.

The primary anxiolytic mechanism of Selank operates through the GABAergic system — specifically, it appears to modulate GABA-A receptor function and/or influence the dynamics of endogenous GABA neurotransmission in ways that produce anxiolysis without the direct GABA-A positive allosteric modulation that characterises classical benzodiazepine action. Unlike benzodiazepines, which bind to the benzodiazepine site on GABA-A receptors and universally produce sedation, cognitive impairment, muscle relaxation, and — with chronic use — dependence and withdrawal, Selank's anxiolytic effects occur without measurable sedation, without cognitive impairment (in fact, with cognitive enhancement), and without evidence of tolerance or dependence in available animal and human studies. This "clean" anxiolytic profile is Selank's most clinically valuable characteristic.

The molecular mechanisms underlying Selank's GABAergic effects are not fully resolved, but research suggests several potential pathways. Selank has been shown to modulate the activity of enkephalin-degrading enzymes — particularly dipeptidyl peptidase IV (DPP-IV) and enkephalinase — reducing the breakdown of endogenous opioid peptides (enkephalins) in the brain. Enkephalins have inhibitory neuromodulatory effects and interact with the GABAergic system, potentially explaining some of Selank's anxiolytic activity through an indirect opioidergic-GABAergic mechanism. Additionally, Selank modulates serotonergic neurotransmission — specifically increasing serotonin turnover in key limbic structures including the amygdala and hippocampus — which may contribute to its anxiolytic and mood-stabilising effects through pathways parallel to those exploited by SSRIs, but without the SERT (serotonin transporter) inhibition mechanism of traditional antidepressants.

The nootropic (cognitive-enhancing) effects of Selank are consistently reported in both animal models and human studies and include improvements in working memory, declarative memory consolidation, attention, and mental stamina under stress. These cognitive benefits occur at the same doses that produce anxiolysis — a unique profile that makes Selank mechanistically distinct from all conventional anxiolytics, which universally impair cognition at anxiolytic doses. The neurobiological basis of these cognitive effects likely involves Selank's stimulation of BDNF (brain-derived neurotrophic factor) expression in the hippocampus and cortex — multiple studies have shown Selank significantly upregulates BDNF mRNA and protein levels, which correlates with improved memory and neuroprotection. Selank also appears to enhance the expression of genes related to dopamine metabolism and transport in key prefrontal and striatal circuits, which may underlie the improved attention, processing speed, and working memory observed in research subjects.

The immunomodulatory activity inherited from Selank's tuftsin ancestry adds an additional dimension to its pharmacological profile. Tuftsin is a phagocyte-activating peptide, and Selank retains some of this innate immune stimulatory activity — it upregulates macrophage and neutrophil activity and increases resistance to certain infectious challenges in animal models. In human populations with conditions characterised by combined immune suppression and cognitive/emotional dysfunction — which often co-occur in chronic fatigue states, post-viral conditions, and asthenic presentations — this immune-cognitive dual action may provide unique therapeutic value. Russian clinical practice has specifically applied Selank to asthenic conditions with this dual pathology in mind.

The intranasal administration route that is standard for Selank in Russian clinical practice provides a practical, injection-free method of delivery that many researchers find appealing. The olfactory epithelium provides direct pathways for peptide transport from the nasal mucosa to the olfactory bulb and surrounding brain regions — bypassing the blood-brain barrier and achieving meaningful CNS concentrations with doses in the 250–1000 mcg range. This direct nose-to-brain transport is not unique to Selank but is particularly advantageous for a heptapeptide that might otherwise have limited CNS penetration via systemic routes.